New hope for tough myeloma: drug plus radiation trial launches

NCT ID NCT06572605

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests whether combining talquetamab (a targeted antibody drug) with radiation therapy can safely treat multiple myeloma that has spread to organs or soft tissues. About 20 adults with this hard-to-treat condition will receive radiation to the tumor site plus the drug. The goal is to see if the combination is safe and shrinks the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Talquetamab (a monoclonal antibody) and external beam radiation therapy
What this could lead to: If successful, this combination could offer a new treatment option for multiple myeloma that has spread outside the bone marrow, a hard-to-treat condition.
What could go wrong: This is an early-phase trial with only 20 participants, so results may not apply broadly. Side effects from both the drug and radiation are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA MULTIPLE MYELOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.